11 results about "Gastric ph" patented technology

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a streptavidin compound preparation with mucus removing and defoaming functions and a preparation process thereof. The preparation consists of streptavidin, sodium bicarbonate, dimeticone, silicon dioxide, polysorbate 80 and a filler / adhesive. The preparation method comprises the following steps: stirring dimeticone and silicon dioxide at 145-155 DEG C to react for 7-8 hours to form a compound through a step-by-step granulation process, performing wet granulation, mixing active ingredients at low temperature, and finally performing dry granulation and sub-packaging. The method is characterized in that 1) streptavidin and dimeticone synergistically decompose mucin and break bubbles, and double-view interference is synchronously eliminated; the pH value in the stomach is maintained to be 7-10 through sodium bicarbonate, the enzyme activity is guaranteed, step-by-step granulation avoids high-temperature damage to the enzyme structure, and 5-minute rapid disintegration is achieved through the 80-mesh sieve granule control technology. The preoperative process is simplified, the drug synergism is improved, and the preparation is suitable for gastroscopy and other scenes.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection. The compositions may be administered intact, or may be crushed prior to administration.

This invention provides the application of *Bifidobacterium breve* in the preparation of products for treating gastric ulcers and gastric inflammation caused by *Helicobacter pylori*, belonging to the field of microbial technology. The *Bifidobacterium breve* NKU BB1-2 of this invention, with accession number GDMCC NO: 65956, can antagonize *Helicobacter pylori* colonization and alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori*. In vitro, *Bifidobacterium breve* NKU BB1-2 exhibits good antagonistic ability against *Helicobacter pylori*, significantly inhibiting its colonization and growth. Animal experiments show that *Bifidobacterium breve* NKU BB1-2 can alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori* infection in vivo, manifested as reduced gastric mucosal damage, reduced gastric inflammation, and increased gastric pH. Furthermore, *Bifidobacterium breve* NKU BB1-2 can significantly enhance gastric microbial diversity, regulate and improve the gastric microbial structure, and assist in antagonizing and eradicating *Helicobacter pylori* infection.

This invention relates to an orally administrated nutritional supplement for the management of symptoms of irritable bowel syndrome (IBS) and related functional disorders. The composition includes:1) zinc-L-carnosine 60-100 mg per daily dose or an equivalent combination of zinc and L-carnosine providing 16?20 mg elemental Zn and 55-60 mg L-carnosine; 2) extract of Boswellia serrata resin with 25-35% total AKBA yielding 60-90 mg AKBA; 3) a probiotic blend 30-100 billion CFU that includes, at least, one strain from the genera Streptococcus, Bifidobacterium, and Lactobacillus. The active ingredients are incorporated into an acid-resistant or slow-release pharmaceutical form which limits their release in gastric pH and releases them when the pH is "greater than or equal to" 5.5, ensuring their integrity until they reach the intestine. The combination of the three above components strengthens the intestinal barrier, reduces intestinal inflammation, and restores the intestinal microbiota, providing comprehensive support to patients with IBS and related functional intestinal disorders.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.

To provide an amorphous solid dispersion ("ASD") comprising dasatinib, a pharmaceutical composition comprising ASD, and a method of treatment comprising administration of the pharmaceutical composition.SOLUTION: Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions can be used in methods of treating a proliferative disorder, such as cancer, or in methods of delivering dasatinib to a patient regardless of whether the patient is concurrently using a gastric acid reducing agent or the patient has an elevated gastric pH. The composition may be particularly suitable for patients suffering from achlorhydria or hypoacidity, or Helicobacter pylori infection.SELECTED DRAWING: Figure 7

The invention belongs to the field of medical instruments, and relates to a gastric juice ph detection stomach tube device. The device comprises a tube body, a detection end and an analysis end, wherein the detection end and the analysis end are respectively connected to the far end and the near end of the tube body and are in communication connection; the tube body is of a multi-layer coaxial structure and sequentially comprises an inner tube, a supporting tube and an outer tube from inside to outside in the radial direction, and the far end of the inner tube is connected with the detection end. The detection end can extend into the stomach of a human body to collect gastric juice ph detection signals, the analysis end receives and processes the signals, and efficient, accurate, convenient and real-time detection of gastric juice ph is achieved. The clamped supporting pipe supports the inner pipe and the outer pipe by means of the structural strength of the supporting pipe, it is guaranteed that the pipe body is straight when stretching into the pipe body and stable during working, blockage of a liquid flowing path or position deviation of the detection end is avoided, and stable detection is guaranteed.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.